|
MONTREAL, QUEBEC--(Marketwire - Nov. 1, 2012) - Alethia Biotherapeutics Inc., a privately held biotechnology company focusing on the development of therapeutic monoclonal antibodies announced today that it has closed a new financing. Alethia will use the proceeds to fund primarily its lead program. The financing included participation of current major investors comprising AgeChem Venture Fund, BDC Venture Capital and GO Capital in addition to a long-term partner and shareholder of the company, Cellscript of Wisconsin. |
